• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Will Blink Triple Care’s Preservative Free Launch Reshape Bausch + Lomb’s (BLCO) Consumer Eye Care Narrative?

    Simply Wall St·06/07/2026 00:24:55
    Listen to the news
    • Bausch + Lomb has launched Blink Triple Care Preservative Free eye drops in the U.S., offering instant, long-lasting dry eye relief in a preservative-free, multi-dose format now rolling out across major national retailers.
    • This launch extends the Blink franchise into a preservative-free, lipid-based formulation that targets both moisture retention and tear evaporation, reinforcing the company’s focus on differentiated consumer eye care solutions.
    • Next, we’ll examine how this preservative-free Blink Triple Care launch fits into Bausch + Lomb’s broader consumer growth story and investment narrative.

    Explore 30 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

    Bausch + Lomb Investment Narrative Recap

    Bausch + Lomb’s story really comes down to whether you believe its broad eye health portfolio can convert category expansion into durable, profitable growth, despite current losses and a still‑leveraged balance sheet. The Blink Triple Care Preservative Free launch supports the consumer eye care catalyst around dry eye, but on its own does not materially change the core near term swing factors, which remain execution on Vision 27 margin initiatives and the risk that dry eye demand or pricing falls short of expectations.

    Among recent announcements, the May 2026 U.S. introduction of PreserVision AREDS3 vitamins feels most relevant alongside Blink Triple Care Preservative Free. Both deepen the over the counter eye health portfolio and lean into consumer self care trends, which analysts already cite as a key driver of higher quality revenue and operating leverage. Together, they highlight how Bausch + Lomb is steadily adding new formulations across dry eye and retina health that could influence how the consumer catalyst unfolds.

    Yet against this product progress, investors should also weigh the risk that dry eye markets and willingness to pay for newer therapies expand more slowly than expected, which could...

    Read the full narrative on Bausch + Lomb (it's free!)

    Bausch + Lomb's narrative projects $5.9 billion revenue and $252.2 million earnings by 2028. This requires 5.7% yearly revenue growth and a $557.2 million earnings increase from $-305.0 million.

    Uncover how Bausch + Lomb's forecasts yield a $17.25 fair value, a 12% upside to its current price.

    Exploring Other Perspectives

    BLCO 1-Year Stock Price Chart
    BLCO 1-Year Stock Price Chart

    Some analysts were already far more optimistic, assuming revenue could reach about US$6.0 billion and earnings about US$242.7 million, so news like Blink Triple Care Preservative Free might either support that view or challenge it depending on how you think about dry eye market growth and competition.

    Explore 5 other fair value estimates on Bausch + Lomb - why the stock might be worth over 2x more than the current price!

    Form Your Own Verdict

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    • A great starting point for your Bausch + Lomb research is our analysis highlighting 3 key rewards that could impact your investment decision.
    • Our free Bausch + Lomb research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bausch + Lomb's overall financial health at a glance.

    Contemplating Other Strategies?

    Opportunities like this don't last. These are today's most promising picks. Check them out now:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.